Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas
OBJECTIVES:
- Determine the therapeutic activity of imatinib mesylate (in terms of objective response
and progression-free survival at 6 months) in patients with gliomas.
- Determine the safety of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to glioma
(glioblastoma multiforme vs anaplastic oligodendroglioma or mixed oligoastrocytoma vs
anaplastic astrocytoma or recurrent low-grade astrocytoma).
Patients receive oral imatinib mesylate once or twice daily. Treatment repeats every 4 weeks
for up to 9 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 2 months for 6 months and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 77 patients (29 patients with glioblastoma multiforme, 24
patients with anaplastic oligodendroglioma or mixed oligoastrocytoma, and 24 patients with
anaplastic astrocytoma or recurrent low-grade astrocytoma) will be accrued for this study.
Interventional
Primary Purpose: Treatment
Eric Raymond, MD, PhD
Study Chair
Gustave Roussy, Cancer Campus, Grand Paris
United States: Federal Government
EORTC-16011-26013
NCT00039364
March 2002
Name | Location |
---|